Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NHS

Melanoma drug pembrolizumab gets NICE backing

The National Institute for Health and Care Excellence (NICE) is recommending in draft guidance that pembrolizumab (Keyruda) be made available on the NHS for the treatment of some patients with advanced melanoma (pictured)

Source: Shutterstock.com

NICE recommends in draft guidance that pembrolizumab be made available to patients with melanoma where their disease has progressed despite being treated with other therapies

The National Institute for Health and Care Excellence (NICE) recommends in draft guidance that pembrolizumab (Keytruda) be made available on the NHS for the treatment of some patients with advanced melanoma. 

The proposal comes just over a month after drug’s positive scientific opinion — which had made the product available to some skin cancer patients under the UK government’s Early Access to Medicines (EAMs) scheme — expired. Under the EAMS scheme, drugs in development that do not have a licence are made available when there is a high unmet clinical need. Pembrolizumab was the first drug to be approved under the scheme. 

On 7 September 2015, NICE in its draft guidance recommends that pembrolizumab be made available to patients with melanoma in cases where the disease has progressed despite being treated with ipilimumab and, for BRAF V600 mutation-positive disease, a BRAF or MEK inhibitor. 

Its availability, says NICE, is conditional on its manufacturer Merck Sharp & Dohme providing it at a discount in an agreed patient access scheme. Pembrolizumab is currently commercially available at the price of £1,315 per 50mg vial. 

The NICE recommendation is out for consultation until 22 September 2015, with the final guidance expected to be published in October 2015. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069304

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Prescribing Medicines for Children

    Prescribing Medicines for Children

    Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.

    £60.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The National Institute for Health and Care Excellence (NICE) is recommending in draft guidance that pembrolizumab (Keyruda) be made available on the NHS for the treatment of some patients with advanced melanoma (pictured)

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.